Literature DB >> 20660298

Cooperation between cyclin E and p27(Kip1) in pituitary tumorigenesis.

Audrey Roussel-Gervais1, Steve Bilodeau, Sophie Vallette, France Berthelet, André Lacroix, Dominique Figarella-Branger, Thierry Brue, Jacques Drouin.   

Abstract

Cushing's disease is caused by glucocorticoid-resistant pituitary corticotroph adenomas. We have previously identified the loss of nuclear Brg1 as one mechanism that may lead to partial glucocorticoid resistance: this loss is observed in about 33% of human corticotroph adenomas. We now show that Brg1 loss of function correlates with cyclin E expression in corticotroph adenomas and with loss of the cell cycle inhibitor p27(Kip1) expression. Because Brg1 is thought to have tumor suppressor activity, the present study was undertaken to understand the putative contribution of cyclin E derepression produced by loss of Brg1 expression on adenoma development. Overexpression of cyclin E in pituitary proopiomelanocortin cells leads to abnormal reentry into cell cycle of differentiated proopiomelanocortin cells and to centrosome instability. These alterations are consistent with the intermediate lobe hyperplasia and anterior lobe adenomas that were observed in these pituitaries. When combined with the p27(Kip1) knockout, overexpression of cyclin E increased the incidence of pituitary tumors, their size, and their proliferation index. These results suggest that cyclin E up-regulation and p27(Kip1) loss-of-function act cooperatively on pituitary adenoma development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660298      PMCID: PMC5417399          DOI: 10.1210/me.2010-0091

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  55 in total

Review 1.  Living with or without cyclins and cyclin-dependent kinases.

Authors:  Charles J Sherr; James M Roberts
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

2.  Antagonism between Nur77 and glucocorticoid receptor for control of transcription.

Authors:  A Philips; M Maira; A Mullick; M Chamberland; S Lesage; P Hugo; J Drouin
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

4.  Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF.

Authors:  H S Zhang; M Gavin; A Dahiya; A A Postigo; D Ma; R X Luo; J W Harbour; D C Dean
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

5.  Pituitary hyperplasia in glycoprotein hormone alpha subunit-, p18(INK4C)-, and p27(kip-1)-null mice: analysis of proteins influencing p27(kip-1) ubiquitin degradation.

Authors:  Ricardo V Lloyd; Katharina H Ruebel; Shuya Zhang; Long Jin
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

6.  The bicoid-related homeoprotein Ptx1 defines the most anterior domain of the embryo and differentiates posterior from anterior lateral mesoderm.

Authors:  C Lanctôt; B Lamolet; J Drouin
Journal:  Development       Date:  1997-07       Impact factor: 6.868

7.  Developmental dependence on NurRE and EboxNeuro for expression of pituitary proopiomelanocortin.

Authors:  Pierre-Luc Lavoie; Lionel Budry; Aurélio Balsalobre; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2008-04-03

8.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

9.  TIF1beta/KAP-1 is a coactivator of the orphan nuclear receptor NGFI-B/Nur77.

Authors:  Juliette Rambaud; Julien Desroches; Aurélio Balsalobre; Jacques Drouin
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

10.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Authors:  David N Reisman; Janiece Sciarrotta; Weidong Wang; William K Funkhouser; Bernard E Weissman
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

View more
  28 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Adult pituitary cell maintenance: lineage-specific contribution of self-duplication.

Authors:  David Langlais; Catherine Couture; Marie Kmita; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2013-06-10

3.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

4.  Gene mutations in Cushing's disease.

Authors:  Qi Xiong; Wei Ge
Journal:  Biomed Rep       Date:  2016-07-29

5.  EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.

Authors:  Hidenori Fukuoka; Odelia Cooper; Anat Ben-Shlomo; Adam Mamelak; Song-Guang Ren; Dave Bruyette; Shlomo Melmed
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

6.  Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.

Authors:  Ning-Ai Liu; Takako Araki; Daniel Cuevas-Ramos; Jiang Hong; Anat Ben-Shlomo; Yukiko Tone; Masahide Tone; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2015-05-05       Impact factor: 5.958

7.  p21, an important mediator of quiescence during pituitary tumor formation, is dispensable for normal pituitary development during embryogenesis.

Authors:  Pamela Monahan; Ashley D Himes; Agata Parfieniuk; Lori T Raetzman
Journal:  Mech Dev       Date:  2011-12-01       Impact factor: 1.882

8.  Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.

Authors:  Ning-Ai Liu; Hong Jiang; Anat Ben-Shlomo; Kolja Wawrowsky; Xue-Mo Fan; Shuo Lin; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

Review 9.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

10.  The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling.

Authors:  Lionel Budry; Aurélio Balsalobre; Yves Gauthier; Konstantin Khetchoumian; Aurore L'honoré; Sophie Vallette; Thierry Brue; Dominique Figarella-Branger; Björn Meij; Jacques Drouin
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.